Public Patent Foundation
Protecting the Public Domain » Pfizer Lipitor Patent

Pfizer Lipitor Patent

In September 2004, the Public Patent Foundation filed a formal request with the United States Patent and Trademark Office to revoke Pfizer Inc.'s patent on Lipitor, touted by the pharmaceutical giant as being "the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world." In its filing, PUBPAT submitted prior art showing the patent, which issued in October 1999 and is not otherwise due to expire until 2016, was anticipated by earlier work of other inventors and, as such, should have never been granted. The PTO granted PUBPAT's request in December 2004 and rejected the patent in June 2005. In November 2005, Pfizer conceded to give up its original broad claims.

Related Documents

Related News

© 2003 - 2015 Public Patent Foundation | Contact | RSS